Turning the focus to advanced-stage HCC, Tanios S. Bekaii-Saab, MD, offers comprehensive insights on first- and second-line treatment options.
FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer
Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Approaching End-of-Life Discussions With Directness and Compassion
Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers
Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.
ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers
Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.